An intelligence hub innovating and accelerating groundbreaking therapies to address unmet medicinal needs

Please enter subscribe form shortcode


100+

Years of Experience

ABOUT

We have come to understand that single-target medicines alone, or when combined among themselves, are not enough to stop CANCER and immune-related diseases.


With a complex network of over 20,000 gene targets associated with cancer progression, a single-target drug is like A WARRIOR FACING MULTIPLE BATTALLIONS. This leads to unsustained therapeutic benefits and adaptive drug resistance.

We are therefore using unique intelligence to identify and accelerate a pipeline of groundbreaking adjuvants (MAd-DP™) to enhance and sustain efficacy of single-target medicines against multiple CANCERs and associated immune-related diseases.

Our MAd-DP™ combines with all drug modalities

  • Small molecules
  • Nucleic acids
  • Peptides
  • Vaccines
  • Monoclonal and bispecific antibodies
  • Recombinant proteins
  • Antigen-heteropolymers
  • Antibody drug conjugates (ADCs)
  • Cell-Gene therapies
  • Herbal/natural products
  • Combination therapies

Our drug advancement scope involves

  • Research
  • Pre-clinical
  • Clinical
  • Market authorization
  • Product lifecycle
How

We Are

Using a 360-degree science and technology diligence model in accelerating our understanding of MEDICINAL GAPs in treating challenging immune-related diseases such as CANCER, AUTOIMMUNE DISEASES, HEPATITIS B, DRUG-RESISTANT INFECTIONS etc. We are then innovating on the druggable opportunities for a sustainable pipeline of ADJUVANTS (MAd-DP™).

Growing an Intelligence Hub

By assembling passionate and innovative minds from academia to industry (from novice to the retired) to apply our diligence model for RIGOR and SPEED to patients.

READ MORE

Partnering with medicinal companies

To accelerate groundbreaking combination therapies to the millions of PATIENTS who are longing for hope.

READ MORE

An intelligence hub innovating and accelerating groundbreaking therapies to address unmet medicinal needs.
Need to Partner with us?

Get In Touch